Valuation: Alaunos Therapeutics, Inc.

Market Cap 45.47L 38.97L 36.51L 33.35L 62.94L 43Cr 63.56L 4.31Cr 1.68Cr 22Cr 1.71Cr 1.67Cr 72Cr P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 31.62L 27.1L 25.39L 23.19L 43.77L 30Cr 44.2L 3Cr 1.17Cr 15Cr 1.19Cr 1.16Cr 50Cr EV / Sales 2024
19,59,38,500x
EV / Sales 2025 1,16,47,61,400x
Free-Float
84.7%
Yield 2024 *
-
Yield 2025 -
1 day+4.07%
1 week-4.79%
Current month-4.79%
1 month-7.73%
3 months-26.03%
6 months-42.81%
Current year-44.58%
1 week 1.69
Extreme 1.69
1.97
1 month 1.69
Extreme 1.69
2.05
Current year 1.69
Extreme 1.69
4.04
1 year 1.69
Extreme 1.69
4.59
3 years 1.31
Extreme 1.3137
32.85
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 02/07/2025
Director of Finance/CFO 42 22/02/2025
Director TitleAgeSince
Director/Board Member 57 16/12/2020
Chairman 63 22/09/2023
Director/Board Member 72 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
06/08/26 Free

Chief Executive Officer

4,363 0.1787%
23/07/26 Free

Director

8,138 0.3332%
23/07/26 Free

Chief Executive Officer

4,568 0.1870%
Change 5-day change 1-year change 3-year change Capi.($)
+4.07%-4.79%-9.14%-91.46% 45.47L
+3.31%-3.70%+61.03%+103.64% 7.14TCr
+1.73%+1.87%+49.35%+90.37% 6.42TCr
+1.09%+22.96%+8.55%-3.03% 2.86TCr
-0.07%-3.56%-3.45%+467.26% 2.71TCr
-2.78%+5.95%+55.58%+12.15% 2.73TCr
-1.09%+0.93%+37.69%-17.41% 2.05TCr
+1.02%+6.43%+269.42%+420.34% 1.94TCr
-0.57%-0.57%+7.19%+538.65% 1.6TCr
+3.98%+6.78%+49.66%+157.94% 1.41TCr
Average +1.06%+3.54%+52.59%+167.85% 2.88TCr
Weighted average by Cap. +1.18%+3.31%+55.45%+154.92%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.09 0.04 0.48 0.04 0.04 1.59 0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.24 0.02 0.02 0.8
Net income -46.79L -40.09L -37.57L -34.32L -64.76L -45Cr -65.4L -4.43Cr -1.73Cr -23Cr -1.76Cr -1.72Cr -75Cr -41.76L -35.78L -33.53L -30.63L -57.8L -40Cr -58.37L -3.96Cr -1.54Cr -20Cr -1.57Cr -1.53Cr -67Cr
Net Debt -10.91L -9L -9L -8L -15.1L -10Cr -15.25L -1.03Cr -40.23L -5.25Cr -40.96L -40.07L -17Cr -13.85L -11.87L -11.12L -10.16L -19.17L -13Cr -19.36L -1.31Cr -51.06L -6.66Cr -52L -50.87L -22Cr
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
25/26/25 $1.790 +4.07% 19,282
24/26/24 $1.720 -2.27% 4,348
21/26/21 $1.760 -2.22% 16,142
20/26/20 $1.800 -4.26% 38,800
19/26/19 $1.880 0.00% 3,416

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock